Literature DB >> 46053

Medical manipulation of the ductus arteriosus.

R B Elliott, M B Starling, J M Neutze.   

Abstract

Prostaglandin E-1 was infused into two children with cyanotic congenital heart-disease where patency of the ductus arteriosus was necessary to maintain arterial oxygen saturation. With each infusion oxygen saturation rose, probably as a result of dilatation of the ductus. Administration of the non-specific antagonist of prostaglandin synthesis, indomethacin, to one patient was associated with a fall in arterial saturation. The prevention of ductus closure by p.g.E-1 infusions over the first few weeks of life is a possiblility.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 46053     DOI: 10.1016/s0140-6736(75)91432-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  33 in total

1.  Transposition of the Great Arteries.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-12

Review 2.  Novel drug targets for ductus arteriosus manipulation: Looking beyond prostaglandins.

Authors:  Elaine L Shelton; Gautam K Singh; Colin G Nichols
Journal:  Semin Perinatol       Date:  2018-05-10       Impact factor: 3.300

3.  New uses for acetylsalicylic acid and other prostaglandin antagonists.

Authors:  E M Cooperman
Journal:  Can Med Assoc J       Date:  1977-08-20       Impact factor: 8.262

Review 4.  Prostaglandin E1: first stage palliation in neonates with congenital cardiac defects.

Authors:  S C Reddy; A Saxena
Journal:  Indian J Pediatr       Date:  1998 Mar-Apr       Impact factor: 1.967

5.  Pharmacological manipulation of the ductus arteriosus.

Authors:  E D Silove
Journal:  Arch Dis Child       Date:  1986-09       Impact factor: 3.791

Review 6.  The future potential of eicosanoids and their inhibitors in paediatric practice.

Authors:  T Shimizu
Journal:  Drugs       Date:  1998-08       Impact factor: 9.546

7.  Association between prophylactic indomethacin and death or bronchopulmonary dysplasia: A systematic review and meta-analysis of observational studies.

Authors:  Erik A Jensen; Elizabeth E Foglia; Barbara Schmidt
Journal:  Semin Perinatol       Date:  2018-05-10       Impact factor: 3.300

8.  Prostaglandin Availability and Association with Outcomes for Infants with Congenital Heart Disease.

Authors:  Brady S Moffett; Joshua M Garrison; Aimee Hang; Shaine A Morris; Rocky Tsang; Kimberly Dinh; Pamela Griffiths; Ronald Bronicki; Paul A Checchia
Journal:  Pediatr Cardiol       Date:  2015-10-24       Impact factor: 1.655

9.  Transcutaneous PO2 monitoring in infants with cyanotic congenital heart disease treated with prostaglandin E1.

Authors:  K J Kimble; R L Ariagno; P Pitlick
Journal:  Pediatr Cardiol       Date:  1983 Apr-Jun       Impact factor: 1.655

10.  Maintaining patency of the ductus-arteriosus for palliation of cyanotic congenital cardiac malformations. The use of prostaglandin E1 and formaldehyde infiltration of the ductal wall.

Authors:  J Hatem; R M Sade; J K Upshur; A R Hohn
Journal:  Ann Surg       Date:  1980-07       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.